<DOC>
	<DOCNO>NCT01375296</DOCNO>
	<brief_summary>Sirolimus-eluting stent ( SES ) proven improve outcome patient significant coronary artery diseae ( &gt; 70 % lumen diameter narrow ) . But , acute coronary syndrome may occur intermediate lesion ( 50 % -70 % lumen diameter narrow ) , effect SES patient remain unclear . Here investigator hypothesize application China-made SES may improve clinical outcome set .</brief_summary>
	<brief_title>China Made Sirolimus Eluting Stent Intermediate Lesion</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>age 1880 year old gender native coronary lesion narrow 5070 % vessel size 2.54.0 diameter without informed consent , ST elevation myocardial infarction within 7 day , leave main lesion , bypass graft , restenosis abnormal liver function randomization , active hepatitis muscular disease , impaired renal function serum creatinine level &gt; 3mg/dl , impair leave ventricular function LVEF &lt; 30 % , participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2009</verification_date>
</DOC>